Enzymotec has developed a new DHA-delivery system that is capable of improving DHA bio-availability.
Earlier this year Enzymotec had concluded an animal and human study on a proprietary structured derivative of the DHA-phospholipid system, exhibiting a better DHA availability over fish DHA or mixtures of DHA and phospholipids and consequently a superior biological effect, thus supporting past scientific literature and the benefits of using advanced DHA delivery systems.
Enzymotec, a lipid nutrition company, is the developer and producer of CardiaBeat for CVD prevention, SharpPS for cognitive enhancement, and InFat for better calcium and energy absorptions as well as easy digestion for infants. More info: Orly Farkash, firstname.lastname@example.org; 972-4-6545112.
Enzymotec Announces New DHA-Based Supplement
Published October 31, 2005
blog comments powered by Disqus